Development of a Janus Kinase (JAK) Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis

While highly efficacious in treating rheumatoid arthritis (RA), the approved JAK inhibitor, Tofacitinib (Tofa, CP-690 550), has dose-dependent toxicities that limit its clinical application. In this study, we have examined whether a prodrug design that targets arthritic joints would enhance Tofa’s t...

Full description

Saved in:
Bibliographic Details
Published in:Mol Pharm
Main Authors: Wei, Xin, Wu, Jianbo, Zhao, Gang, Galdamez, Josselyn, Lele, Subodh M., Wang, Xiaoyan, Liu, Yanzhi, Soni, Dhruvkumar M., Purdue, P. Edward, Mikuls, Ted R., Goldring, Steven R., Wang, Dong
Format: Artigo
Language:Inglês
Published: 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6078779/
https://ncbi.nlm.nih.gov/pubmed/29966420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.8b00433
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items